Browse the evidence

There are no statistically significant differences in peak EMG amplitude between high-load and low-load resistance exercises.

Practitioners can expect similar peak muscle activation levels regardless of load intensity during bench press.

Inhibition of NO synthase (NOS) reduces skeletal muscle glucose uptake during contraction.

Inhibiting NOS may impair glucose uptake during exercise, affecting performance.

The increase in skeletal muscle glucose uptake due to NO is independent of blood flow.

Understanding that NO's effect on glucose uptake is independent of blood flow can inform training strategies.

There is currently insufficient evidence to recommend the addition of electrolytes to beverages for players during a game resulting in sweat losses of < 4% of body weight.

Electrolyte supplementation may not be necessary for players with low sweat losses during games.

There were no significant differences in hormonal responses (IGF-1 and testosterone) between the two training systems.

Practitioners can expect similar hormonal responses regardless of the resistance training system used.

More studies are needed to support the long-term effects of long-acting amylin analogues in relevant populations.

Practitioners should be aware that while promising, the long-term efficacy of these treatments is not yet established.

The analysis was limited to studies using dual-energy X-ray absorptiometry (DXA) for measuring fat-free mass.

Practitioners should be aware of the limitations of DXA in assessing body composition.

GLP-1RAs may have renal benefits driven by new-onset macroalbuminuria.

GLP-1RAs may be considered for patients with T2D who also have renal concerns, particularly regarding macroalbuminuria.

The relationship between BMI and LDL cholesterol change was not observed on higher-carbohydrate diets.

Practitioners should consider that the effects of BMI on LDL cholesterol may differ with carbohydrate intake levels.

Perioperative semaglutide use is associated with increased residual gastric content (RGC) in patients undergoing elective esophagogastroduodenoscopy.

Clinicians should consider the timing of semaglutide administration in relation to elective procedures to mitigate RGC risk.

The contribution of the GIP receptor-activating component of tirzepatide to its effects is uncertain.

Further research is needed to clarify how GIP receptor activation contributes to the effects of tirzepatide.

Baseline muscle protein synthesis (MPS) during androgen deprivation therapy (ADT) is suppressed relative to age-matched controls.

Practitioners should be aware that ADT may lead to reduced muscle protein synthesis in patients.

The implementation of MBSAQIP and ERAS protocols has significantly improved the quality of care for all bariatric patients.

Healthcare providers should adopt MBSAQIP and ERAS protocols to enhance patient outcomes.

High systolic blood pressure was the second leading cause of cardiometabolic mortality, except in Bangladesh.

Monitoring and managing blood pressure is crucial for reducing cardiometabolic risks.

GLP-1 RAs showed long-term protective effects on renal outcomes and adverse events.

GLP-1 RAs may provide long-term benefits for kidney health in obese individuals without T2D.

Collagen supplementation did not change integrated MPS rates compared to the RDA.

Collagen may not be effective for enhancing muscle protein synthesis in older males.

GIPR agonism may reduce gastrointestinal adverse effects associated with GLP-1R agonism.

GIPR agonists may help mitigate gastrointestinal side effects for patients using GLP-1R agonists.

Concurrent exposure to liraglutide and a GIPRA is hypothesized to produce fewer GI adverse effects than exposure to liraglutide alone.

This suggests a potential strategy for reducing side effects in patients using liraglutide.

There is limited literature on the impact of weight loss medications for plastic surgeons and their patients.

Plastic surgeons need to seek more information on the effects of these medications.

Plastic surgeons must understand the indications, contraindications, and perioperative management of weight loss medications.

Surgeons should educate themselves on these medications to ensure safe practices.

Obesity prevalence is projected to grow by 40% in the next decade.

Health professionals should prepare for increased obesity-related health issues.

The incidence of obesity-related glomerulopathy has increased 10-fold in recent years.

Increased awareness and monitoring for kidney issues in obese patients is necessary.

In patients with cardiometabolic HFpEF, tirzepatide showed a 58% lower risk of hospitalization for heart failure or all-cause mortality compared with sitagliptin.

Tirzepatide may also be a beneficial treatment option for patients with HFpEF and cardiometabolic conditions.

Activity energy expenditure decreased throughout pregnancy in both groups, but there was no difference between high gainers and low+ideal gainers.

Practitioners should be aware that activity levels may decrease during pregnancy, affecting overall energy expenditure.